CAR-T updateSeptember 27, 2023 - AbbVie terminates its collaboration and license agreement with Caribou focused on advancing allogeneic CAR-T therapeutics for two unspecified AbbVie programs.
Caribou revealed in its SEC filing on Tuesday that AbbVie has “elected to not advance these two programs.” Following the contract’s termination, all licenses granted under the agreement will also end.
Caribous CRISPR-based genome editing tools use an RNA guide molecule to help locate its target DNA sequence
Earlier this week, the Abbvie also terminated its contract with Maryland- and Shanghai-based I-Mab. The partners were previously working on the anti-CD47 antibody lemzoparlimab, which they had been developing for myelodysplastic syndrome and acute myeloid leukemia.
https://www.biospace.com/article/abbvie-terminates-caribou-car-t-contract-in-culling-of-cancer-pipeline/